Nestlé launches Vital Pursuit frozen meals aimed at GLP-1 users

Nestlé has begun selling a frozen-food line aimed at people on GLP-1 weight loss drugs, sold under a new brand called Vital Pursuit. The company calls it the first food brand of its own created for that group ^[3]. Food Dive reported it marked Nestlé's first new major U.S. brand in close to 30 years ^[1].

Twelve items are involved, reaching selected stores around the country by the fourth quarter, with labels suggesting $4.99 or less each. Retailers set their own prices. The range runs from bowls with whole grains or protein pasta to sandwich melts and pizzas, and includes gluten-free and air-fryer-ready choices ^[3].

Nestlé says each item is portion-aligned to fit the appetite of someone on a weight loss medication, carries a good amount of protein and fiber, and supplies nutrients such as vitamin A, potassium, calcium or iron ^[3].

"As the use of medications to support weight loss continues to rise, we see an opportunity to serve those consumers," Steve Presley, chief executive officer of Nestlé North America, said in the announcement ^[3]. Tom Moe, who leads the company's U.S. meals division, said Vital Pursuit would grow to include "more product formats" ^[3].

Nestlé pointed to several figures to explain the bet: one in 60 U.S. adults received a GLP-1 prescription in 2023, according to the American Pharmacists Association, and J.P. Morgan Research expects the U.S. total to approach 30 million users by 2030, or about 9% of the population. Nestlé also cited federal health statistics showing 49% of American adults said they had tried to lose weight at some point during a year ^[3].

Rivals are moving in similar directions. General Mills has introduced smaller packages along with protein-forward items, and its CEO, Jeff Harmening, told an industry conference that "anti-obesity drugs will have a lasting influence on the food market" ^[1]. Conagra Brands has attached a "GLP-1 friendly" label to certain Healthy Choice frozen meals ^[1], and Danone released an Oikos yogurt drink marketed to people using the drugs ^[1].

Purchasing data explains the interest. A Morgan Stanley survey of 300 GLP-1 patients found daily calorie intake fell 20% to 30%; roughly two-thirds reported buying fewer sugary drinks, and 62% said they drank less alcohol ^[2]. Cornell University and Numerator researchers found households with at least one person on such a drug trimmed grocery spending about 6% within six months, with savory snacks down 11% ^[2]. A KFF poll cited by Food Dive put current GLP-1 use at about one in eight adults, for weight loss, diabetes or another condition ^[1].

How long people stay on the drugs is less clear. One study found that 50% to 75% of those who begin them quit within a year ^[1]. Erin Lash, a senior director of consumer equity research at Morningstar, said most food companies "don't seem overly concerned to this point" because "consumers are still indulging," though she called preparing for a permanent market prudent ^[1].

Why it matters for patients

Shoppers taking semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound) now have freezer-aisle options labeled around a reduced appetite. Vital Pursuit items are priced at $4.99 or less and emphasize protein, fiber and controlled portions ^[3]. Food Dive noted that with appetite suppressed, nutrient and vitamin density matters more for protecting muscle mass ^[1].

Nothing in Nestlé's announcement indicates the meals were tested in people on GLP-1 medications, and no standard has been reported for what qualifies a product to carry a "GLP-1 friendly" label ^[1][3]. Distribution is partial as well: the company said the line would go to select retailers nationwide, not every store ^[3].

What happens next

Nestlé has not disclosed which chains will carry Vital Pursuit or which items are already on shelves ^[3]. Projections for how many people will use these drugs differ. Morgan Stanley sees 24 million U.S. users, about 7% of the population, by 2035 ^[2], while J.P. Morgan Research puts the figure near 30 million by 2030 ^[3]. A Circana report cited by Food Dive estimated that households with GLP-1 users would account for more than a third of food and beverage sales over the next five years ^[1].